Vaxelis 50090-7542-00
Generic: Diphtheria And Tetanus Toxoids And Acellular Pertussis, Inactivated Poliovirus, Haemophilus B Conjugate And Hepatitis B Vaccine
- Manufacturer
- A-S Medication Solutions
- Dosage Form
- Injection, Suspension
- Route
- Intramuscular
- Product Type
- Vaccine
- Marketing Start
- December 21, 2018
- Listing Expires
- December 31, 2026
- Application
- BLA125563
Active Ingredients
| Ingredient | Strength |
|---|---|
| Bordetella Pertussis Filamentous Hemagglutinin Antigen (formaldehyde Inactivated) | 20 ug/.5mL |
| Bordetella Pertussis Fimbriae 2/3 Antigen | 5 ug/.5mL |
| Bordetella Pertussis Pertactin Antigen | 3 ug/.5mL |
| Bordetella Pertussis Toxoid Antigen (glutaraldehyde Inactivated) | 20 ug/.5mL |
| Clostridium Tetani Toxoid Antigen (formaldehyde Inactivated) | 5 [Lf]/.5mL |
| Corynebacterium Diphtheriae Toxoid Antigen (formaldehyde Inactivated) | 15 [Lf]/.5mL |
| Haemophilus Influenzae Type B Capsular Polysaccharide Meningococcal Outer Membrane Protein Conjugate Antigen | 3 ug/.5mL |
| Hepatitis B Virus Subtype Adw Hbsag Surface Protein Antigen | 10 ug/.5mL |
| Poliovirus Type 1 Antigen (formaldehyde Inactivated) | 29 [D'ag'U]/.5mL |
| Poliovirus Type 2 Antigen (formaldehyde Inactivated) | 7 [D'ag'U]/.5mL |
| Poliovirus Type 3 Antigen (formaldehyde Inactivated) | 26 [D'ag'U]/.5mL |
Drug Class
Actively Acquired Immunity [PE]Actively Acquired Immunity [PE]Actively Acquired Immunity [PE]
Selected Package
50090-7542-00Selected10 SYRINGE in 1 PACKAGE (50090-7542-0) / .5 mL in 1 SYRINGE (50090-7542-1)